Page 6 of 26
PE18.{3,6,14} | Vaccine Classification and Schedules — SDL Guide (Part 3)
Self-Assessment
Self-directed learning requires active engagement with the material, not just passive reading. The following questions are designed to test your recall of exact NIS schedule details, your ability to apply contraindication logic to clinical scenarios, and your understanding of why newer vaccines have been added to the schedule. Attempt each question independently before checking your notes or the schedule table — the process of retrieval practice (recalling information without reference) is itself a learning mechanism that strengthens long-term memory, as established by cognitive-load theory and Gagné's instructional design principles. This is particularly important for immunization, where the schedule contains many specific numerical thresholds (ages, doses, volumes) that must be recalled accurately in clinical practice. Work through all five questions; any item you cannot answer confidently identifies a gap to revisit before your clinical posting and ward examination.
- What is the exact NIS schedule for the pentavalent vaccine? At what age, dose, and route is it administered?
- A 4-month-old on high-dose prednisolone (2 mg/kg/day) for nephrotic syndrome is brought for vaccination. Which NIS vaccines at this age are safe to administer, and which should be deferred?
- Name three newer vaccines now recommended by IAP but not universally in UIP, and state the specific indication for each.
- A parent asks why their child needs both OPV and fIPV at 6 weeks — they think it is 'double-dosing' for polio. How do you explain the difference?
- A child has had only 1 dose of pentavalent at 6 weeks, then the family relocated. The child is now 9 months old. Should you restart the pentavalent series, or continue from dose 2?
SELF-CHECK
Under the current NIS, at which age is the first dose of fIPV (fractional inactivated poliovirus vaccine) given, and by which route?
A. At birth, orally
B. At 6 weeks, intradermally (0.1 mL ID)
C. At 6 weeks, intramuscularly (0.5 mL IM)
D. At 9 months, subcutaneously
Reveal Answer
Answer: B. At 6 weeks, intradermally (0.1 mL ID)
fIPV is administered intradermally (ID) at 0.1 mL (one-fifth the full IPV dose) at 6 weeks and again at 14 weeks under the current NIS. This fractional intradermal dose achieves comparable seroconversion to the full IM dose due to the high density of antigen-presenting cells in the dermis. It replaced type-2 OPV after global monovalent OPV-2 withdrawal in 2016. It is NOT given at birth, orally, or IM.